Physician profile
Sheeja Francis
NPI 1578680195
$22,660.85
in general payments reported to CMS, 2019-2025
46 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $9,427 · 2021: $2,903 · 2022: $577 · 2023: $670 · 2024: $4,871 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,440 · Food and Beverage: $3,015 · Travel and Lodging: $1,479 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,440.00 |
| Food and Beverage | $3,015.00 |
| Travel and Lodging | $1,478.67 |
| Education | $146.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11,213.57 | 2020-2025 | Tremfya, Erleada, Simponi Aria |
| Gilead Sciences, INC. | $4,568.06 | 2020 | |
| Janssen Scientific Affairs, LLC | $2,750.00 | 2021 | |
| Abbvie INC. | $629.29 | 2019-2025 | |
| Amgen INC. | $523.52 | 2019-2025 | Tavneos, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $332.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $318.85 | 2021-2025 | Saphnelo |
| Pfizer INC. | $228.41 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.19 | 2019-2024 | |
| Antares Pharma, INC. | $170.58 | 2019-2025 | Xyosted |
| Lilly USA, LLC | $169.96 | 2019-2025 | Taltz, Omvoh, Olumiant |
| Sumitomo Pharma America, INC. | $163.94 | 2024-2025 | Gemtesa |
| Ucb, INC. | $135.78 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $118.63 | 2024-2025 | Benlysta |
| Urogen Pharma, INC. | $97.63 | 2023-2024 | Jelmyto |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheeja Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.